8-K: Gyre Therapeutics Secures China CDE Alignment for Hydronidone

Gyre Therapeutics' subsidiary, Gyre Pharmaceuticals, achieved CDE alignment for a conditional approval pathway and priority review eligibility for its anti-fibrotic therapy, Hydronidone, in China.

Summary

• Gyre Pharmaceuticals completed a Pre-New Drug Application (Pre-NDA) meeting with China's Center for Drug Evaluation (CDE) regarding Hydronidone, a first-in-class anti-fibrotic therapy.
• The CDE agreed that existing Phase 3 clinical data for Hydronidone generally support a conditional approval filing for chronic hepatitis B (CHB)-associated liver fibrosis, including early (compensated) cirrhosis.
• Hydronidone meets the criteria for inclusion in China's Priority Review and Approval Program for Innovative Drugs, subject to formal filing, acceptance, and regulatory review.
• The NMPA previously granted Hydronidone Breakthrough Therapy Designation in March 2021.
• Topline results from the Phase 3 trial showed 52.85% of treated patients achieved 1-stage fibrosis regression at Week 52, compared with 29.84% in the placebo group (p=0.0002).
• A confirmatory clinical trial (Phase 3c) will be conducted to evaluate liver-related clinical outcomes to support potential conversion from conditional approval to regular approval.
• Gyre Pharmaceuticals plans to submit an NDA for conditional approval of Hydronidone in the first half of 2026.

Sentiment

Score: 8

Explanation: The filing indicates significant positive progress in the regulatory pathway for a key drug candidate in a large market, with CDE alignment and priority review eligibility based on strong Phase 3 data. This is a very favorable development for the company's future prospects.

Positives

• Achieved CDE alignment on a clear regulatory pathway for conditional approval of Hydronidone in China.
• Hydronidone meets the criteria for China's Priority Review and Approval Program for Innovative Drugs, potentially accelerating regulatory review.
• Phase 3 clinical data demonstrated statistically significant fibrosis regression, with 52.85% of treated patients achieving 1-stage regression versus 29.84% in the placebo group (p=0.0002).
• The Phase 3 trial also achieved a key secondary endpoint evaluating improvement in liver inflammation without fibrosis progression and showed a favorable safety profile.
• Hydronidone addresses a significant unmet medical need in patients with CHB-associated liver fibrosis, for whom no approved anti-fibrotic therapies currently exist in China.
• Hydronidone received Breakthrough Therapy Designation from the NMPA in March 2021, recognizing its potential to address a serious condition.

Negatives

• Conditional approval requires a subsequent confirmatory clinical trial (Phase 3c) to support full regulatory approval.
• Priority review eligibility is subject to formal filing, acceptance, and regulatory review, not a guaranteed outcome.

Risks

• Ability to execute on clinical development strategies.
• Positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials.
• Timing or likelihood of regulatory filings and approvals.
• Competition from competing products.
• Impact of general economic, health, industrial or political conditions in the United States or internationally.
• Sufficiency of capital resources and ability to raise additional capital.
• Supply chain and distribution delays and challenges.

Future Outlook

Gyre Pharmaceuticals plans to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to final data readiness and applicable regulatory procedures. The company will also conduct an additional confirmatory clinical trial (Phase 3c) designed to evaluate liver-related clinical outcomes to support potential conversion from conditional approval to regular approval in China.

Management Comments

• "We are encouraged by the positive and constructive Pre-NDA dialogue with the CDE and the alignment achieved on a clear regulatory pathway."
• "This milestone reflects the strength of our Phase 3 clinical data and supports our plans to advance Hydronidone toward conditional approval in China."
• "Hydronidone addresses a significant unmet medical need in patients with CHB-associated liver fibrosis, for whom there are currently no approved anti-fibrotic therapies."

Industry Context

CHB-associated liver fibrosis represents a significant unmet medical need in China, with an estimated 2.6 million patients having diagnosed, compensated, clinically significant liver fibrosis (F2-F4) who may be eligible for anti-fibrotic intervention. Hydronidone, if approved, would be a first-in-class anti-fibrotic therapy addressing this large and underserved patient population, positioning Gyre to capture a substantial market share.

Stakeholder Impact

• Shareholders: Positive impact due to significant progress in regulatory approval for a key drug, potentially increasing future revenue and market value.
• Patients (in China): Potential access to a first-in-class anti-fibrotic therapy for CHB-associated liver fibrosis, addressing a significant unmet medical need.
• Employees: Positive impact from successful drug development milestones and potential for increased company growth.

Next Steps

• Submit an NDA for conditional approval of Hydronidone in the first half of 2026.
• Conduct a confirmatory clinical trial (Phase 3c) to evaluate liver-related clinical outcomes to support potential conversion from conditional approval to regular approval in China.

Key Dates

Recommendation

The company has achieved a critical regulatory milestone for Hydronidone in China, securing CDE alignment for a conditional approval pathway and priority review eligibility based on robust Phase 3 data. This significantly de-risks the drug's path to market in a large, underserved patient population. The potential for conditional approval in the first half of 2026, followed by a confirmatory trial for full approval, positions Gyre for substantial future revenue growth and market penetration in the CHB-associated liver fibrosis market. This positive regulatory progress, coupled with the unmet medical need, makes the stock highly attractive for investment.

Keywords

Gyre Therapeutics, Hydronidone, liver fibrosis, CHB, chronic hepatitis B, NMPA, CDE, NDA, conditional approval, priority review, biopharmaceutical, fibrosis-first therapies, China, Phase 3 trial, Breakthrough Therapy Designation, anti-fibrotic therapy